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Abstract
Late disease recurrence (more than 5 years after initial diagnosis) represents a clinical challenge in the treatment and
management of estrogen receptor-positive breast cancer (BC). An international workshop was convened in Toronto, Canada,
in February 2018 to review the current understanding of late recurrence and to identify critical issues that require future
study. The underlying biological causes of late recurrence are complex, with the processes governing cancer cell dormancy,
including immunosurveillance, cell proliferation, angiogenesis, and cellular stemness, being integral to disease progression.
These critical processes are described herein as well as their role in influencing risk of recurrence. Moreover, observational
and interventional clinical trials are proposed, with a focus on methods to identify patients at risk of recurrence and possible
strategies to combat this in patients with estrogen receptor-positive BC. Because the problem of late BC recurrence of great
importance, recent advances in disease detection and patient monitoring should be incorporated into novel clinical trials to
evaluate approaches to enhance patient management. Indeed, future research on these issues is planned and will offer new
options for effective late recurrence treatment and prevention strategies.
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We convened an international workshop that involved clini-
cians, trialists, scientists, and funders with expertise and/or in-
terest in addressing the problem of late recurrence in estrogen
receptor-positive (ERþ) breast cancer (BC). The workshop was
held in Toronto, Canada, on February 15–16, 2018, and its goal
was to review current knowledge about the issue of late recur-
rence and to make recommendations for future research strate-
gies (a list of participants is included as an Supplementary
Appendix, available online). This article summarizes the work-
shop discussions regarding the biology underlying late recur-
rence with a focus on tumor dormancy, potential approaches to
identify late recurrences before they are clinically apparent, and
key research directions. A companion article (2) describes the
current understanding of the problem of late recurrence as well
as clinical considerations around late recurrence. Here, we re-
view diagnostic testing approaches to predict or identify late re-
currence and propose a framework for approaching potential
research directions, including prognostic biomarkers and thera-
peutic interventions. Herein, we define late recurrence as recur-
rence 5 or more years after diagnosis, which corresponds to the
minimum recommended course of adjuvant endocrine therapy
(ET) and accounts for approximately one-half of all recurrences.
Late Recurrences in ER1 Breast Cancer: A Question of
Tumor Dormancy
To diagnose and treat late recurrences in patients with ERþ BC,
it is essential to consider the biology of these events. There
were two competing models discussed at the workshop: indo-
lency vs dormancy. In the former, preexisting disseminated
micrometastases in distant organs from the breast might be
growing at a constant, but very slow, rate so that their clinical
appearance occurs much later after diagnosis and treatment of
the primary cancer. In the latter, preexisting micrometastases
in distant organs are dormant or remain in a balanced equilib-
rium of cellular turnover for prolonged periods of time. At some
point, some of these are “tipped” into rapid growth, or in other
words, escape or exit dormancy to appear as clinically apparent
metastases.
Overall, the attendees of the workshop favored the dor-
mancy model because the indolence model may relate more to
relatively early recurrences, for example, those that occur in the
first few years after diagnosis. Different rates of tumor growth
would explain the diversity among the time to first recurrence—
some within months, whereas others may be years later. In the-
ory, these are the types of cancer recurrence in which adjuvant
chemotherapy given soon after diagnosis has the greatest benefit.
It was felt that these cancers are overrepresented by ER- negative
tumors, regardless of human epidermal growth factor receptor 2
(HER2 or ERBB2) status, as well as ERþ cancers with high prolifer-
ative thrust (so-called luminal B BCs).
The dormancy model might itself be split into two separate
models. In one, a single cell or a small accumulation of cancer
cells has exited the active cell cycle and exists in a resting phase
(G0). In other words, they are quiescent. In the second, a cluster
of malignant cells making up a micrometastasis is in equilib-
rium between proliferation and programmed cell death. This
scenario might be termed “balanced cell proliferation and
death.” These two models are supported by preclinical studies
and may not be mutually exclusive, either between patients or
even within a single individual (2–4).
These models raise the issue of what generates dormancy,
and why and how metastases escape it. Metastatic dormancy
may result from a complex relationship between the genetic
status of the systemic tumor cells and their microenvironment,
including both the local and systemic status of the immune sys-
tem and other systemic host factors, such as the presence of
nutrients, growth, and angiogenic factors. The epigenetic state
of systemic tumor cells may also play a role, given the possibil-
ity that epigenetic reprogramming may be required for these
cells to adapt and thrive in foreign microenvironments.
Dormant cancer cells often resemble normal stem cells, which
also undergo periods of dormancy followed by activation and
self-renewal (5,6). Malignant cells exhibiting markers of stem-
ness are frequently found in primary BC as well as distant me-
tastases. In one study, 65% of disseminated tumor cells (DTCs)
within the bone marrow of patients exhibited a stem cell-like
phenotype (7). Cells exhibiting these stem cell properties as well
as specific surface markers have also been detected in the blood
of patients with BC (8).
Alterations in any or all of the factors discussed above may
potentially contribute to escape from dormancy, and the mech-
anisms of escape from dormancy appear to be multi-factorial
(4). The complexity of these interactions is evidenced by vari-
ability in metastatic latency, as described above among various
intrinsic subtypes of BCs (Figure 1). One mechanism may be a
subsequent genetic “hit” that was not necessary for establish-
ment of a micrometastases in a foreign site (9) but that induces
a quiescent group of cells to reenter the cell cycle or tips a group
of cells in balanced cell proliferation and death towards a state
favoring growth over equilibrium. For example, p38 MAPK sig-
naling is associated with maintenance of quiescence in breast
and other cancer cells (4,10,11). Conversely, escape from dor-
mancy is associated with activation of intracellular pathways
associated with proliferation and growth such as the Akt, extra-
cellular signal-regulated kinase 1/2, and Src signaling networks
(12–14), or Nuclear Receptor Subfamily 2 Group F Member 1, an
orphan nuclear receptor of the retinoic acid receptor family (15).
Alternatively, or in concert with new genetic changes, altera-
tions in host factors may also play a role in escape from dor-
mancy. For example, it has long been proposed that the
immune system may play a critical role in tumor dormancy
through immunosurveillance. In preclinical models, both the
innate and adaptive immune systems detect and eliminate can-
cer cells as a means of anticancer defense (3,16). If this mecha-
nism is disturbed, some cancer cells may emerge as resistant to
elimination, or masked from detection, and initiate the develop-
ment of a macrometastatic lesion.
Although this theory is appealing, it is likely that the interac-
tions between the immune system and dormant cancer cells
are more complex. In certain contexts, inflammation may have
a paradoxical effect by stimulating emergence from dormancy,
for instance through the action of neutrophil-derived factors
(17). Moreover, there is no evidence that immunosuppressed
patients, such as those with acquired immune deficiency or
solid organ transplants, have either a higher risk of BCs or a
higher risk of subsequent recurrences (early or late) following
diagnosis (18,19). Indeed, tolerance to components of the im-
mune system is an important part of evolution of multi-cellular
species; otherwise, the human race would be plagued with
auto-immune diseases. However, recent studies have identified
both check-points that control the immune response as well as
pharmaceutical agents to inhibit them (20–22). These immune
checkpoint inhibitors have resulted in exceptional responses
and even cures in metastatic melanoma, non-small lung cancer,
colorectal and bladder cancers, among other malignancies.
Recently, activity with checkpoint inhibitors in metastatic BC
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(MBC) has been reported, but these trials have been primarily
conducted in patients with ER- and HER2-negative (“triple neg-
ative”) MBC (23–25). Such therapeutic approaches might be an
exciting strategy to enhance or activate immune surveillance if
they can be instituted safely in the future, but their relevance in
ERþ BC is currently unclear.
Tumor dormancy may also be induced by the absence of suf-
ficient nutrients and oxygen to support the level of dissemi-
nated cell proliferation necessary for tumor growth. This state
of angiogenic impairment limits the ability of cancer cells to
grow beyond micrometastases, because cells can proliferate
but lack the blood supply required for full metastatic outgrowth
(26,27). Exit from angiogenic dormancy, or the angiogenic
switch, can be stimulated either locally within the microenvi-
ronment or systemically via alterations in circulating factors
(28). In particular, vascular endothelial growth factor is impli-
cated in the stimulation of angiogenesis, and placenta growth
factor may play a role in metastatic outgrowth in the bone (29–
31). However, although initially met with great enthusiasm,
anti-angiogenic therapy with bevacizumab, a monoclonal anti-
body against vascular endothelial growth factor, has resulted in
minimal benefit in the metastatic or adjuvant settings in BC
(32–34). These disappointing results may suggest that either the
hypothesis of tumor-induced neo-angiogenesis is incorrect or
Basement membrane
Blood vessel
Invasion
Intravasation Extravasation at secondary site
Metastatic outgrowth
Cancer cell
Dormant tumor cell
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Growth factor/cytokine
Circulating tumor cells
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Figure 1. Metastatic spread of human breast cancer. Metastatic spread and tumor outgrowth at a distant site require the completion of a number of critical steps, each
involving complex interactions between cancer cells and the local microenvironment. Cells at the primary site invade tissue architecture and spread through the base-
ment membrane (1: invasion), after which they enter blood vessels (2: intravasation). These cells then enter the circulation, where they must survive in the blood ves-
sels before adhering to a vessel wall at a distant site. Cancer cells in the bloodstream can now be detected by various methods and enumerated to provide prognostic
information. After adhering to a vessel wall, cancer cells then extravasate and enter normal tissue at a secondary site (3: extravasation). Interactions between cancer
cells and the local microenvironment, which may include various growth factors, cytokines, and immune cells, may lead to the induction of dormancy for long periods
of time (4: dormancy). Later, changes in these same factors, or the presence of new molecules, can induce an exit from dormancy, leading to full metastatic outgrowth
and disease recurrence (5: metastatic outgrowth).
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that this particular agent is insufficient to prevent it.
Furthermore, relevant to the issue of late recurrence in ERþ BC,
subset analyses of several trials have suggested that if bevacizu-
mab is effective at all in BC, the benefit is limited to patients
with ER-negative disease (35).
The most common metastatic site for patients with ERþ BC
is bone. This observation suggests that bone exhibits unique
properties that allow disseminated BC cells to survive and colo-
nize this tissue microenvironment. Cancer cells that enter the
bone localize to specific niches and often exhibit distinct inter-
actions with the normal stroma. In particular, tumor cells are
often found in regions of bone containing cells of osteoblast lin-
eage where they interact via specific proteins and ligands to es-
tablish colonization and dormancy (36,37) (Figure 2). In
preclinical models, escape from dormancy in the bone is a com-
plex process characterized by paracrine interactions between
the cancer cells and osteoblast and osteoclast activation
(4,36,38). Therefore, therapies designed to reduce metastatic
outgrowth in the bone, such as bisphosphonates or RANK li-
gand inhibitors, represent potentially effective disease manage-
ment strategies (39–42). The use of adjuvant bisphosphonates
has provided some benefit (42,43), but effects are limited to
postmenopausal women and not necessarily to those with ERþ
disease. Likewise, evidence that adjuvant use of the RANK li-
gand inhibitor denosumab reduces risk of recurrence (early vs
late) in ERþ postmenopausal BC patients receiving aromatase
inhibitor therapy is not convincing (44).
Taken together, these considerations suggest that the (epi)-
genetic makeup of the cancer cells themselves as well as the
levels of numerous immune, inflammatory, and angiogenic fac-
tors may be responsible for dormancy and that alterations in
them may account for release from dormancy and late recur-
rences of ERþ BCs. Therefore, understanding these factors may
provide potential diagnostic and therapeutic opportunities for
the prevention of disease recurrence. However, the field is lim-
ited by the lack of prospectively conducted clinical research of
patients who have achieved 5 or more years without recur-
rence, and further research is required to determine if a patient
with a previously diagnosed ERþ BC can safely discontinue all
therapy, should continue on extended ET, or should add or
switch to a completely novel therapeutic.
Theoretical Classification of Dormancy Status in
Patients with ER1 BC
We propose that patients with a previously diagnosed ERþ inva-
sive BC and who reach 5 or more years without recurrence may
be divided into one of three theoretical categories (Figure 3): 1)
no dormant cells present, 2) cells present, but still dormant, and
3) cells present that have escaped dormancy. It is important to
note that patients may move between categories over time, for
example, from category 2 to category 3, as cells exit dormancy.
At present these categories are theoretical, because adequately
validated tests to detect residual cancer cells are not yet available.
Although definitive classification into these categories is not
RANK CXCR4
CXCL12
Integrins
E-Cadherin
RANKL N-Cadherin
Annexin-R 
IL-6R
AXL
IL-6
Annexin GAS6
Osteoblasts
Osteoclasts
Osteocytes
Bone lining cells
Colonization Dormancy
Colonizing cancer cells
Dormant cancer cells
Figure 2. Colonization of bone by breast cancer (BC) cells. BC cells frequently metastasize to the bone where a series of complex interactions between tumor cells and
normal cells in the microenvironment mediate colonization and dormancy. For example, RANKL and CXCL12 are produced by normal cells and attract tumor cells to
home towards the bone and initiate bone colonization. Cadherins and integrins are also implicated in this process. Conversely, annexin, IL-6, and GAS6 are secreted by
normal cells within the bone niche and engage their cognate receptors on tumor cells to enable survival within the bone microenvironment and subsequent dormancy.
RANK-L: RANK Ligand, CXCL12: C-X-C motif chemokine 12, also known as stromal cell-derived factor 1 (SDF1), IL-6: interleukin-6, GAS6: growth arrest-specific-6.
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currently possible for any individual patient, in the sections be-
low we suggest how future tests based on DTCs, circulating tu-
mor cells (CTCs), and/or ctDNA may someday enable
categorization. Although we use the term “dormancy” here and
describe three distinct categories, we recognize that other cellu-
lar mechanisms may contribute to early and/or late recurrence,
and there is likely a continuum of dormancy including mixed
cell populations that culminate in clinical development of me-
tastases once a critical threshold is reached.
Category 1: No Dormant Cells Present
These patients do not have any evidence of distant, dormant, or
active malignancy, such as DTCs detectable in bone marrow,
CTCs, or ctDNA (see below). These patients would have a high
chance of being cured and thus spared additional therapy.
Category 2: Cells Present but Still Dormant
These patients have some sort of potentially detectable evi-
dence of viable cells present in distant organs. Evidence might
include DTCs, CTCs, or ctDNA, with tumor cell or DNA bio-
marker tests suggesting the detected cells are viable but still
dormant. These patients are likely at risk of recurrence, but the
absolute annual risk and time course of risk are unknown and
need to be quantified. Therapeutic strategies might be to con-
tinue current therapy, because it appears to be “working,”
switch to or add something that could be effective but still has
low toxicity if patients are currently on ET, or consider initiat-
ing therapy (endocrine or other) if patients are not on treat-
ment. A subcategory of this group might include patients who
have detectable DTCs or CTCs, but if the markers were available,
these cells could be shown to be short-lived terminally differen-
tiated bulk cells with no evidence of “stemness” and no viable
potential. These patients would have no or very low chance of
recurrence and could safely stop ET or any other therapy
designed to prevent late distant recurrence.
Category 3: Cells Present, Have Escaped Dormancy
These patients exhibit some detectable preclinical marker indic-
ative of recurrence (DTCs, CTCs, ctDNA), and theoretical tumor
biomarker tests, if available, would demonstrate that these cells
have escaped dormancy. These patients are at high risk of dis-
tant recurrence in a relatively short time. The challenge is to
both detect tumor cells or DNA and determine that tumor cells
Patients
End of adjuvant hormone therapy
No dormant cells
detected
Potentially 
cured
Dormant cells
present
Cells remain 
dormant or 
non-viable
Potentially 
cured
Cells escape 
dormancy
Clinical 
metastases
Incurable
- Stimulus
- Discontinuation of 
adj. hormone Tx
- Spontaneous
Treatment
Effective
Ineffective
(1)
(2) (3)
Figure 3. Theoretical classification of dormancy status in patients with estrogen receptor-positive breast cancer and possible outcomes. Three categories are possible:
Those with 1) no dormant cells present, 2) cells present, but still dormant, and 3) cells present that have escaped dormancy; although patients may move between cate-
gories over time. Adj ¼ adjuvant; Tx ¼ treatment.
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are no longer dormant. If this can be accomplished, one might
consider treating these patients as if they had established
metastases in the hopes of returning cells to dormancy or pre-
venting clinical metastases. At present, palliation is the
evidence-supported goal of therapy for MBC, because prior and
outdated prospective randomized trials have suggested no ben-
efit in early vs later treatment of patients with occult but
impending relapse (45). Therefore, one should emphasize inclu-
sion of such patients in clinical trials, either to readdress the is-
sue of switching to (or initiating) an existing standard therapy,
such as a different ET, or to ask important questions of novel
therapies, such as CDK4/6 inhibitors, which are proven effective
in the metastatic setting (46,47). One could also consider using
the DTC-CTC-ctDNA characterization results to provide
“Precision Targeted Therapy” or modern immunotherapy
within a matching-type trial.
Although it is appealing to consider these three categories,
at present the technology to identify them with any certainty is
in its infancy. Nonetheless, we propose that studies using mod-
ern and emerging technologies attempting to do so, as well as
interventional trials directed towards each group, are impera-
tive, including possible trials evaluating the benefit of reduced
or extended adjuvant ET vs completion of the standard course
for the low-risk patients in group 1. It is worth noting that we
may find that tissue-based or blood-based biomarkers associ-
ated with risk of late relapse are best measured at the time of
diagnosis and that later emergence of detectable tumor-
associated abnormalities reflects relapse and inferior action-
ability; all of these possibilities need to be explored.
New Technologies for Identifying Potential Exit From
Dormancy and Predicting Late Recurrence
Disseminated Tumor Cells
Identification of DTCs, or indication of their presence, has been
the focus of substantial translational research over the last sev-
eral decades (Table 1). Several investigators have reported that
up to 30% of patients with newly diagnosed BC have bone mar-
row micrometastases at the time of initial diagnosis. A pooled
analysis of these data demonstrates that having bone marrow
micrometastases is associated with higher rates of recurrence,
but the risk is not absolute (48,49).
Furthermore, in one study, bone marrow micrometastases
were identified in 15% of patients who were at least 3 years
from initial diagnosis (50). The risk of distant recurrence over
the succeeding 24 months was 21% compared with 7% for those
who did not have detectable bone marrow micrometastases
(P< .001). In another report, the incidence of bone marrow me-
tastases remained high (>16%) at 2–3 years after diagnosis but
declined to 6% at the last date evaluated (51).
Furthermore, work by Janni and colleagues (52) demon-
strated that the hazard ratio (HR) for distant recurrence for
those with bone marrow micrometastases vs those without was
greater than fourfold 5 years after initial diagnosis, which rep-
resented approximately 2–3 years after the bone marrow was
analyzed (Figure 4). However, the risk of distant recurrence for
those with positive bone marrow in the succeeding 2–3 years af-
ter bone marrow analysis was only approximately 40%.
Furthermore, after this time, the presence of previously positive
bone marrow was no longer associated with higher risk of re-
currence compared with those with negative bone marrows (al-
though both groups continued to develop distant recurrences).
Specifically, there was no overall survival (OS) disadvantage for
patients with DTC during the follow-up period from 6–10 years
(after initial diagnosis). These data, combined with the invasive
nature of obtaining bone marrow aspirates, has resulted in DTC
evaluation being omitted from routine follow-up programs.
Consequently, detection of tumor cells in blood became the fo-
cus of ongoing research aimed at identifying biomarkers of re-
sidual disease and distant recurrence in patients with cancer.
Circulating Biomarkers: “Liquid Biopsies”
Evaluation of circulating markers, or so-called liquid biopsies,
for prognosis in BC patients has also been an active area of re-
search (Table 1). This has been a priority area of interest given
the greater convenience and patient compliance with obtaining
peripheral blood compared with bone marrow. Most studies to
date have addressed circulating tumor-associated proteins, tu-
mor cells, and cell-free tumor DNA. However, most of these
have been studied in patients at or relatively near the time of
Table 1. Methods for identifying potential exit from dormancy with potential utility in predicting late recurrence*
Assay Method Advantages Limitations
DTCs Detection of cytokeratin-positive cells in
bone marrow aspirates by ICC
Robust assays
Strong prognostic value at
diagnosis
Invasive sample collection
DTC detection not an absolute in-
dicator of recurrence
Circulating tumor
antigens
Detection of tumor-associated proteins
(CA15-3, CA27.29, CEA, CA125) in blood
Ease of sample collection
Inexpensive
Multiple assays available
Prone to false positives
Little evidence demonstrating util-
ity in patient monitoring
CTCs Enumeration of EpCAM-positive cells
(CellSearch), or enrichment-free multi-
parametric detection of cells (EPIC
Sciences), in blood
Ease of sample collection
CellSearch FDA approved
Highly amenable to serial
measurements
CTC detection not an absolute in-
dicator of recurrence
Clinically validated thresholds
needed
ctDNA Targeted (PCR-based) or nontargeted (ge-
nome or exome sequencing), methyla-
tion analysis detection of DNA in blood
Ease of sample collection
Highly amenable to serial
measurements
Provides data on tumor genetics
Sensitive capture and detection
methods needed
Clinical utility in monitoring recur-
rence not validated
*CEA ¼ carcinoembryonic antigen; CTC ¼ circulating tumor cell; ctDNA ¼ circulating tumor DNA; DTC ¼ disseminated tumor cell; EpCAM ¼ epithelial cell adhesion
molecule; FDA ¼ Food and Drug Administration; ICC ¼ immunocytochemistry; PCR ¼ polymerase chain reaction.
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initial diagnosis, with few data available regarding patients
who are 5 or more years without recurrence.
Circulating Tumor-Associated Antigens
Circulating tumor-associated antigens are proteins, including
products of the MUC1 gene (detected by commercially available
CA15-3 or CA27.29 assays) as well as carcinoembryonic antigen
and the CA125 antigen (53). These markers are elevated in ap-
proximately 75%, 50%, and 25%, respectively, of patients with
MBC. Several studies have demonstrated that in asymptomatic
patients being followed after primary diagnosis and treatment,
a rising circulating tumor biomarker measured serially over
time has a positive predictive value of 75–100% for subsequent
detectable metastases, depending on the criteria to determine
“rising” and the succeeding follow-up period. These markers are
also fraught with false-positive findings, often associated with
inflammatory but benign conditions of liver, gastrointestinal
tract, and lung and mesothelial tissues (53). Only a single
small study has randomly assigned such patients to having se-
rial circulating tumor markers evaluated vs routine follow-up
and failed to demonstrate any OS benefit for the former (54).
Neither the American Society of Clinical Oncology nor the
Figure 4. Patient outcomes according to the presence or absence of disseminated tumor cells (DTCs) in bone marrow. Kaplan–Meier plots of long-term survival and out-
come according to the presence or absence of DTCs in bone marrow. Vertical dotted lines indicate the cutoff point at 5 years of follow-up used in the piecewise Cox regression
modeling. A–D, All patients in the study. E–H, Patients receiving adjuvant systemic treatment. CI ¼ confidence interval; HR ¼ hazards ratio. CSS ¼ cancer-specific survival;
DFS¼ disease free survival; DDFS¼ distant disease free survival; OS¼ overall survival. ~n¼ “to”. Reprinted from (52). Copyright©(2011) with permission from AACR.
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National Cancer Center Network guidelines recommend
monitoring patients in this situation with these markers at pre-
sent (45).
Circulating Tumor Cells
CTCs are elevated in 25–50% of patients with MBC (55). The de-
sire to identify non-MBC patients who are at risk of disease re-
currence has led to the evaluation of CTCs as a prognostic
marker in the operable setting (Table 2). The detection of CTCs
before initiation of chemotherapy (using a threshold of 1 CTC
per 7.5 mL blood expressing the epithelial cell adhesion mole-
cule [EpCAM] protein) is consistently associated with reduced
distant disease-free survival and OS (56–59).
Sparano and colleagues (60) have recently reported a pilot
study in which they evaluated the presence of CTCs, measured
using the EpCAM-based CellSearch technology, in over 350
patients who had participated in an adjuvant clinical trial con-
ducted by the Eastern Cooperative Oncology Group and were
4.5–7.5 years post-diagnosis without recurrence. Most, but not
all, of these patients had ERþ disease (60). Eighteen (5%) of these
patients had detectable CTCs (defined as 1 CTC per 7.5 mL
whole blood), and the presence of CTCs was associated with a
10.82-fold higher risk of recurrence (95% confidence interval [CI]
¼ 4.42 to 26.47, P< .01) (Figure 5). In multivariable models, the
relative risk for distant recurrence after a median follow-up of
2.6 years was 13.1 (95% CI ¼ 4.7 to 36.3) (60). However, as with
bone marrow micrometastases, the presence of CTCs was not
an absolute indicator of rapid recurrence. The recurrence rates
over the succeeding 2–3 years of follow-up in the CTC-positive
and CTC-negative groups were approximately 26% and 3%, re-
spectively. Notably, no imaging was performed at the time of
CTC evaluation, and thus it is not clear whether those with posi-
tive CTCs had asymptomatic metastatic disease at the time of
the blood draw or subsequently developed metastatic disease.
Similar, but less striking, results were reported by Janni et al.
(61) for CTCs measured using CellSearch 5 years after chemo-
therapy in patients enrolled in the SUCCESS A trial. In patients
with HRþ disease, the presence of CTCs (>1 CTC per 7.5 cc) was
a statistically significant prognostic factor for recurrence-free
survival in both univariate (HR ¼ 5.14, 95% CI ¼ 1.47 to 18.03,
P¼ .01) and multivariable analyses, adjusted for age, tumor
stage, nodal stage, grade, histological type, and HER2 status (HR
¼ 5.95, 95% CI ¼ 1.14 to 31.16, P¼ .04) (61).
As with the bone marrow findings, the salient increased risk
of recurrence for HRþ patients with at least one CTC supports
the theory that CTC detection might serve as a potential
method of identifying BC patients who at least have dormant
disease (group 2, Figure 3). Furthermore, CTC enumeration may
identify those who have escaped dormancy (Figure 3, group 3),
with a very high risk of disease recurrence after completion of
5 years of ET. However, the short follow-up in these studies
(2.6 years post CTC evaluation in the Sparano study) and the
fact that the positive predictive value for distant recurrence is
far from 100% may indicate that many of these patients still
have dormant disease. Moreover, as was seen with randomized
surveillance vs regular care studies in the past (using imaging
and less sophisticated blood-based tests), early identification
may not confer improved outcome (45).
To date, CTC studies in BC have used EpCAM-based
CellSearch technology and relied on context-specific thresholds
for prognostic utility (>5 CTC per 7.5 cc blood in the metastatic
setting,>1 CTC per 7.5 cc in early BC patients). Other technologies
use approaches that are not EpCAM based, which allow for enu-
meration of cells that may exhibit loss of EpCAM expression, thus
possibly providing a more comprehensive evaluation of CTC
numbers. The use of these newer technologies, potentially cou-
pled with validated biomarkers present on CTCs, may provide en-
hanced prognostic and predictive information. For example, the
EPIC Sciences CTC assay that characterizes an androgen receptor
splice variant (AR-V7) has been used in castration-resistant pros-
tate cancer to predict treatment benefit (62).
Circulating Tumor DNA
The detection of circulating cell free tumor DNA (ctDNA) has
also been investigated for its prognostic potential in BC patients.
In addition, analysis of ctDNA can yield information on the
(epi)genetic composition of the tumor including clonal hetero-
geneity and possible actionable mutations (63). In the meta-
static setting, several studies have demonstrated an association
between the detection of ctDNA and poor outcome (64–66). In
particular, mutations in the gene encoding the estrogen recep-
tor (ER) (ESR1) found in ctDNA from ERþ BC patients are associ-
ated with worse outcome and resistance to ET (aromatase
inhibitors and tamoxifen) (64,67). Furthermore, the ESR1 muta-
tion rate appears to be higher in ctDNA than in metastatic tissue
biopsies, suggesting ctDNA may overcome limitations in sam-
pling and capture heterogeneity better (67,68). Although these
Table 2. CTC detection in newly diagnosed breast cancer cohorts
Study No. of patients Disease stage Detection rate þ Predicts DFS? Predicts OS?
REMAGUS02 (56,85,86) 115 II–III 23% Yes (HR 2.4) Yes (HR 3.0)
GEPARQUATTRO (87,88) 213 I–III 22% Yes (HR 2.1) Yes (HR 3.0)
NEOALTTO (89)* 51 I–III 11% NA NA
NEOZOTAC (90) 95 I–III 18% NA NA
MD Anderson (91) 57 I–III† NA Yes (HR 5.3) Yes (HR 7.0)
MD Anderson (92) 77 III (T4d) 55% No No
MD Anderson (93) 63 III (T4d) NA Yes (HR 4.2) No
BEVERLY-1 and 2 (94) 137 III (T4d) 35% Yes (HR 2.8) Yes (HR 4.3)
JBCRG-07 (95) 34 I-III NA Yes (HR 1.01) NA
IMENEO (59)‡ 2156 I-III 25% Yes Yes (HR 1.1)
*22.5 mL blood assessed. CTC ¼ circulating tumor cell; DFS ¼ disease free-survival; HR = Hazard Ratio; OS ¼ overall survival; Distant metastasis free survival; LRFI ¼
Local recurrence-free interval; + detection defined as presence of at least 1 CTC/7.5 mL blood by the CellSearch assay that detects EpCAM-expressing cells.
†Triple negative tumors.
‡Meta-analysis.
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results support the utility of ctDNA analysis in monitoring
patients and possibly guiding treatment decisions, the field is
relatively new and several issues regarding preanalytical and
analytical factors remain unclear (69,70).
Importantly, although ctDNA is increasingly utilized for
identification of actionable alterations and treatment planning
in metastatic cancer, the clinical utility of ctDNA in early-stage
disease for detecting minimal residual disease and for monitor-
ing recurrence is not yet established (69,71). Nevertheless, pre-
liminary studies have suggested that ctDNA may be present in
up to 50% of patients with localized BC (stages I–III) (72), and
ctDNA detection has demonstrated utility in the prediction of
disease recurrence in at least some patient cohorts (72–75).
However, one must be concerned whether the presence of
ctDNA in patients with ERþ BC who have remained disease free
for several years has the same clinical relevance as it might ear-
lier in the disease course or in established metastatic disease.
Currently, there are no data regarding determination of progno-
sis of ctDNA and late relapse in BC. For example, if the model of
dormancy based on balanced cell proliferation and death is
valid, it is possible that ctDNA may be present from such cells
but may not portend immediate, or even high, risk of recur-
rence. Likewise, the presence of CTCs may also not signify high
risk of recurrence in the context of balanced cell proliferation
and death.
Although ctDNA technologies are currently robust enough to
detect genomic alterations in patients with advanced meta-
static disease, more sensitive technologies to detect minimally
residual disease are still evolving. Planning to use such sensi-
tive ctDNA technologies for clinical decision-making, such as
possible therapy escalation, also raises concerns about the po-
tential for false positives.
Future Directions
All present at the workshop were enthusiastic about initiating
new investigations into the issue of late relapse in patients with
ERþ BC who are 5 or more years from diagnosis without recur-
rence. However, discussions surrounding what exactly the most
important research questions are as well as assay development
and validation (tissue-based multi-factorial assays that risk-
stratify patients based on tumor characteristics at diagnosis,
bone marrow analyses or CTCs, ctDNA, and other circulating
factors that can be measured serially to identify dynamic
changes associated with exit from dormancy or impending re-
currence) were robust. These discussions raised issues of differ-
ent study designs that could be developed, how such studies
would be funded, and whether the research questions could be
addressed using existing resources (eg, biospecimens from on-
going clinical trials).
Diagnostic Studies
Analytical Issues Regarding Liquid Biopsies
A first goal is development of better diagnostics to determine
how likely a patient is to be in one of the three categories iden-
tified (Figure 3) so that clinical strategies could be followed ac-
cordingly. Further goals include generation of interventions
that can be used to prevent late recurrences, either those likely
to occur within a few months of the time of testing or those that
may occur in the distant future.
Assay Development and Validation
Issues surrounding potential variability among various plat-
forms to enrich and enumerate DTCs and CTCs need to be
addressed in pilot studies. Likewise, the technology to identify
and quantify ctDNA is changing rapidly, as is the increasing un-
derstanding of the importance of careful attention to preanalyt-
ical issues such as the proper fixative in the collection tube and
time to specimen processing.
Other issues include establishment of clinically validated
thresholds for recurrence and the value of serial liquid biopsies
to increase the positive and negative predictive values for true
impending recurrence and later in response to therapy. Future
studies should ideally include imaging at the time of liquid bi-
opsies, especially if they appear to be providing an indication of
impending relapse. Importantly, as in the past, prospective tri-
als will be necessary to evaluate whether DTC, CTC, or ctDNA
positivity can identify patients who will benefit from change in
Figure 5. Circulating tumor cell positivity and time to recurrence in patients with hormone receptor-positive breast cancer. CI ¼ confidence interval; CTC ¼ circulating
tumor cell; HR ¼ hazard ratio. Modified and reproduced with permission from (60). Copyright©(2018) American Medical Association. All rights reserved.
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therapy. These trials will need to address each of the different
categories (Figure 3) so that proper clinical utility can be estab-
lished in each use context.
Finally, it is possible that DTC, CTC, and ctDNA may provide
complementary information regarding late recurrences. This
possibility is especially likely in regards to characterization of
tumor cells or DNA as well as quantitation of the detected ana-
lytes. For example, several studies have demonstrated the abil-
ity to phenotype both DTCs and CTCs for expression of
important proteins, such as ER, HER2, Ki67, markers of apopto-
sis, androgen receptor, and others (76). Similarly, cellular ex-
pression of a variety of genes at the RNA level is now
technically feasible (77–80).
It is hoped that such evaluations might provide insight into
whether detected cancer cells are still in, or have escaped from,
dormancy. Furthermore, beyond quantification of ctDNA, deter-
mination of specific genomic (or epigenomic) abnormalities
that might be exploited for treatment with targeted agents or
provide an indication for the use of checkpoint inhibitors offers
an exciting opportunity. As another example, identification of
an ESR1 ligand-binding domain mutation might suggest a
change in therapeutic strategy from aromatase inhibition to a
selective estrogen receptor downregulator such as fulvestrant
or a novel oral agent in development.
Moreover, recent studies have demonstrated the technical
ability to isolate individual DTCs and CTCs and perform geno-
mic analyses, offering the possibility of assessing genomic and
phenotypic intra-patient heterogeneity and leading to informed
combination therapy in the future (81–83).
Observational Studies
Prospective cohort studies of ERþ BC patients at high risk for
late recurrence (based on clinicopathologic characteristics),
with serial measurements (every 6–12 months) of blood and
host factors (ideally combined with imaging when abnormali-
ties are identified) and rigorous ascertainment of recurrences,
will provide important insights into factors that precede late re-
currence, leading to more accurate identification of patients at
risk of late recurrence who could be enrolled in intervention
studies evaluating agents with the goal of preventing disease re-
lapse. A major outcome of these studies would be the identifica-
tion of patients not at risk of recurrence or not at risk within a
specified time frame so that these patients would not be sub-
ject to immediate interventions. These studies would also pro-
vide valuable information regarding the timeline between
appearance of a marker of late recurrence (eg, DTCs, CTC,
ctDNA, or tumor markers) and the appearance of clinically or
radiographically apparent metastases.
The use of such assays that do not require “real-time” analy-
sis would allow more cost-effective research because it is then
possible to conduct nested case-control analyses at a later date
(ie, focused on all patients with recurrence and a matched sub-
set of patients without recurrence). This approach also avoids
ethical issues that might arise if CTCs are found in real time
and no intervention is provided (alternatively, this concern may
be avoided if these patients are offered participation in an inter-
vention trial), but it precludes the conduct of contemporaneous
imaging studies to determine whether clinical metastases are
present at the time of first detection of CTCs or ctDNA.
Such studies could also collect host factor information, with
a focus on a parsimonious group of factors most likely to be as-
sociated with late recurrence. These data may provide insight
into patient-related factors that could contribute to exit from
dormancy, as discussed in the companion article.
One key design issue is the consideration of whether the pa-
tient is currently on ET when biomarkers are examined. The ex-
tent to which tumor-related factors change when ET is stopped
or altered, whether assays performed while on or at completion
of ET predict future recurrence, and whether these assays can
be used to guide immediate treatment decisions (to stop,
change, or continue ET) is not clear.
Interventional Studies
Potential interventional trial strategies are summarized in
Figure 6, which include a “biomarker stratification” trial, in
which all patients are randomly assigned to a novel therapeutic
intervention, or a “biomarker selection” trial, in which only
patients with a positive integral biomarker are selected for ran-
domization to a novel therapeutic intervention. A clinical and
regulatory framework for such an approach is exemplified by
regulatory approval for anti-androgenic agents (apalutamide
and enzalutamide) for the treatment of nonmetastatic castra-
tion-resistant prostate cancer based on the endpoint of
metastasis-free survival, with selection of the high-risk popula-
tion based on a rising serum prostate-specific antigen level (84).
With regard to the biomarker stratification trial, a major ad-
vantage is that it would allow cross-platform comparison of
several integrated biomarkers, with the goal of selecting one or
more that may best predict therapeutic benefit from the inter-
vention and subsequently serve as an integral biomarker to se-
lect for treatment. Furthermore, this type of trial would provide
valuable information pertaining to patients in each category of
dormancy status and how often patients progress from the low-
(1 and 2) to the high-risk (3) categories. A major disadvantage of
this design is that it requires treatment of all patients selected
for high risk based on clinicopathologic features alone, resulting
in overtreatment of the vast majority of trial participants.
A major advantage with the biomarker selection design is
that only patients at highest risk would be included, reducing
the number of trial participants and enhancing the likelihood of
success by selection of patients at highest risk of recurrence.
Major disadvantages include the need to screen a very large
number of patients to identify the biomarker-enriched popula-
tion and the need to rely on one biomarker, or a panel of bio-
markers, that may not have a robust evidence base to support
its use and may not be the optimal biomarker for these
purposes.
A biomarker selection trial could also include serial assays to
screen high-risk populations at multiple time -points after diag-
nosis but before recurrence rather than screen at a single time-
point, or evaluation of assays as an intermediate pharmacody-
namic biomarker of drug response. Both trial designs could also
provide an opportunity to identify biomarkers that distinguish
cells that remain in dormancy vs those that have exited dor-
mancy and have the potential to identify clinically detectable
and incurable distant metastasis.
Funding, Existing Resources, Navigator
In addition to prospectively collecting tissue and/or blood to
test the prognostic and/or predictive utility of a tissue-based
biomarker, samples that have already been collected and stored
in a repository can serve as a precious resource. In 2018, the
National Cancer Institute’s National Cancer Trials Network
(NCTN) Navigator went live (https://navigator.ctsu.org/naviga-
tor/login). The advantage of using NCTN Navigator is that the
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specimens are procured in the context of a clinical trial, with
available information about treatment and clinical outcome.
Researchers can also query based on specific clinical trials and
patient characteristics. Sample availability is currently limited
to phase III NCTN trials for which the primary outcome has
been publicly reported. Potential associated fees and timeline of
concept review and tissue procurement are detailed on the
Navigator website. In addition to NCTN Navigator, there were
discussions of the potential utility of identifying accessible tu-
mor tissue and/or blood from smaller NCTN trials that are not
on NCTN Navigator as well as in non-NCTN repositories that
have annotated clinical information. Most of the biospecimens
that are potentially available through Navigator, however, in-
clude primary tumor biospecimens or blood specimens
obtained at or relatively soon after diagnosis and not blood
specimens obtained 5 or more years after diagnosis in patients
who were cancer-free and subsequently relapsed.
Conclusions
In this workshop, we detailed the potential underlying mecha-
nisms for the development of late recurrence, a significant clini-
cal issue for patients with early-stage ERþ BC. Although it was
recognized that the biology associated with dormancy escape
may be complex and due to various processes, we categorized a
patient’s disease status into three groups to frame the risk
of late recurrence and consideration for therapeutic interven-
tion: 1) no dormant cells present, 2) cells present, but still
dormant, and 3) cells present that have escaped dormancy.
Though there remains enthusiasm about the possible clinical
utility of blood-based methods, such as CTCs and ctDNA, the
role of these assays remains unclear in the early-stage BC set-
ting, including if these markers can precisely discriminate a
patient’s late recurrence risk into one of these categories; this
highlights the need for additional rigorous research on this
topic.
As discussed in the companion article, there is a pressing
need to identify reliable markers of late recurrence risk beyond
standard clinical and pathologic features. Clinical implications
include not only deescalating therapy in patients for whom no
dormant cells are present but also modifying therapy in the
hopes of preventing relapse in those at immediate risk. We dis-
cussed optimizing the preanalytic, analytic, and post-analytic
considerations of the various tissue-based platforms in devel-
opment. In addition, different observational and interventional
designs were detailed, with discussions about discriminating
the prognostic and predictive capacity of an assay (or combina-
tion of assays) and maximizing research opportunities to under-
stand risk in distinct patient populations, such as those still on
anti-estrogen therapy compared with those no longer receiving
treatment.
In conclusion, there is considerable potential for decreasing
the alarming risk of late recurrence in nonmetastatic ERþ BC.
Although there may be a number of mechanisms at play, in-
cluding host factors described in the companion article (2), we
hope to continue moving beyond a one-size- fits-all approach
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Figure 6. Schemas of hypothetical clinical trials including circulating tumor cells and/or other “liquid biopsy” assays as for testing novel treatment intervention to pre-
vent metastasis.
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and thoughtfully stop, continue, or modify therapy based on re-
liable estimates of the likelihood of recurrence. Our hope is that
international collaborations, such as those discussed in this
workshop, will help achieve this goal and ultimately improve
patient outcome.
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